Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages

QR Code

Different Induction of PD-L1 (CD274) and PD-1 (CD279) Expression in THP-1-Differentiated Types 1 and 2 Macrophages

Chun-Yi Lai,1,2,&ast; Po-Chun Tseng,1,2,&ast; Chia-Ling Chen,3 Rahmat Dani Satria,2,4– 6 Yung-Ting Wang,2 Chiou-Feng Lin1,2,7,8 1Core Laboratory of Immune Monitoring, Office of Research & Development, Taipei Medical University, Taipei, 110, Taiwan; 2Department of Microbiology and Immunol...

Description complète

Enregistré dans:

Détails bibliographiques
Auteurs principaux:	Lai CY, Tseng PC, Chen CL, Satria RD, Wang YT, Lin CF
Format:	article
Langue:	EN
Publié:	Dove Medical Press 2021
Sujets:	pma thp-1 macrophage differentiation pd-l1 pd-1 Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Accès en ligne:	https://doaj.org/article/1993b2cf2ff04421bec75a5df2295b0c
Tags:	Ajouter un tag Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires

Immunoexpression of PD-L1 and PD-1 and Its Clinicopathological Correlation in Urothelial Carcinomas
par: Utpal Kumar, et autres
Publié: (2021)

REGULATION OF TLR/RLR GENE ACTIVITY AND SYNTHESIS OF CYTOKINES DURING PHORBOL MYRISTATE ACETATE (PMA)-INDUCED DIFFERENTIATION OF THP-1 MONOCYTES INTO MACROPHAGE-LIKE CELLS
par: T. M. Sokolova, et autres
Publié: (2017)

Treatment-Related Adverse Events with PD-1 or PD-L1 Inhibitors: A Systematic Review and Meta-Analysis
par: Yixi Zhang, et autres
Publié: (2021)

COMPARATIVE CHARACTERISTICS OF THE DEVELOPMENT OF INFLUENZA INFECTION IN MACROPHAGES DIFFERENTIATED FROM MONOCYTES OF THP-1 (INFLUENZA A VIRUSES OF SUBTYPES H1, H5 AND H9)
par: T. M. Sokolova, et autres
Publié: (2018)

New Insights into the Role of PD-1 and Its Ligands in Allergic Disease
par: Miguel Angel Galván Morales, et autres
Publié: (2021)

Various Uses of PD1/PD-L1 Inhibitor in Oncology: Opportunities and Challenges
par: Zhitao Li, et autres
Publié: (2021)

The Potential Advantage of Targeting Both PD-L1/PD-L2/PD-1 and IL-10–IL-10R Pathways in Acute Myeloid Leukemia
par: Laura Jimbu, et autres
Publié: (2021)

Stomach cancer. Clinical significance of the expression of key components of PD-1/PD-L1 immune checkpoint
par: Olga V. Kovaleva, et autres
Publié: (2021)

Clinical observation of the efficacy of PD‐1/PD‐L1 inhibitors in the treatment of patients with advanced solid tumors
par: Miao Wang, et autres
Publié: (2021)

Application of PD-L1, PD-L2, CD30, CD23 and BCL-6 in Diagnosis and Prognostic Evaluation of Primary Mediastinal Large B-cell Lymphoma
par: YUAN Ting, et autres
Publié: (2021)

Clinicoprognostic and Histopathological Features of Guttate and Plaque Psoriasis Based on PD-1 Expression
par: Chang-Jin Jung, et autres
Publié: (2021)

Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy
par: Jing Zhou, et autres
Publié: (2022)

Tumor response as defined by iRECIST in gastrointestinal malignancies treated with PD-1 and PD-L1 inhibitors and correlation with survival
par: Peiyi Xie, et autres
Publié: (2021)

Reconstitution of Monocyte Subsets and PD-L1 Expression but Not T Cell PD-1 Expression in Obstructive Sleep Apnea Patients upon PAP Therapy
par: Christina Polasky, et autres
Publié: (2021)

Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers
par: Yasuhito Mihashi, et autres
Publié: (2021)

Dl-3-N-Butylphthalide Presents Anti-Cancer Activity in Lung Cancer by Targeting PD-1/PD-L1 Signaling
par: Jiang Q, et autres
Publié: (2021)

Kaposi’s Sarcoma-Associated Herpesvirus Increases PD-L1 and Proinflammatory Cytokine Expression in Human Monocytes
par: Kurtis M. Host, et autres
Publié: (2017)

EGCG Inhibits Tumor Growth in Melanoma by Targeting JAK-STAT Signaling and Its Downstream PD-L1/PD-L2-PD1 Axis in Tumors and Enhancing Cytotoxic T-Cell Responses
par: Dinoop Ravindran Menon, et autres
Publié: (2021)

Efficacy of PD‐1/PD‐L1 inhibitors in patients with non‐small cell lung cancer and brain metastases: A real‐world retrospective study in China
par: Jiamin Sheng, et autres
Publié: (2021)

The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis
par: He Ba, et autres
Publié: (2021)

Bone Marrow-Resident Vδ1 T Cells Co-express TIGIT With PD-1, TIM-3 or CD39 in AML and Myeloma
par: Franziska Brauneck, et autres
Publié: (2021)

Role of PD-L1 in licensing immunoregulatory function of dental pulp mesenchymal stem cells
par: Rosanna Di Tinco, et autres
Publié: (2021)

Plasmatic Levels of HSP90α at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors Plus Chemotherapy
par: Shubin Chen, et autres
Publié: (2021)

Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment
par: LAI Yanliang, et autres
Publié: (2021)

Immunotherapy of cancer tumors with inhibition of PD-1 membrane protein and its ligands interaction
par: A. V. Chetveryakov, et autres
Publié: (2021)

Detection of PD-L1 Expression in Temozolomide-Resistant Glioblastoma by Using PD-L1 Antibodies Conjugated with Lipid‑Coated Superparamagnetic Iron Oxide
par: Lee GA, et autres
Publié: (2021)

Correlation between schistosomiasis and CD8+ T cell and stromal PD-L1 as well as the different prognostic role of CD8+ T cell and PD-L1 in schistosomal-associated colorectal cancer and non-schistosomal-associated colorectal cancer
par: Weixia Wang, et autres
Publié: (2021)

Potential Biomarkers for the Efficacy of PD-1-PD-L Blockade in Cancer
par: Grecea M, et autres
Publié: (2021)

PLACENTAL SECRETORY FACTORS INFLUENCE TO THP-1 CELLS PHENOTYPE AND THP-1 CELLS TRANSENDOTHELIAL MIGRATION
par: O. I. Stepanova, et autres
Publié: (2014)

QUANTITATIVE EXPRESSION FEATURES OF PD-1 AND TIM-3 CHECKPOINT MOLECULE RECEPTORS ON CD4⁺ AND CD8⁺ T-CELLS IN BREAST CANCER OF VARYING PROGRESSION DEGREES
par: Yu. A. Shevchenko, et autres
Publié: (2021)

Conditional Deletion of Pdcd1 Identifies the Cell-Intrinsic Action of PD-1 on Functional CD8 T Cell Subsets for Antitumor Efficacy
par: Sukanya Raghavan, et autres
Publié: (2021)

Interplay between IL-10, IFN-γ, IL-17A and PD-1 Expressing EBNA1-Specific CD4<sup>+</sup> and CD8<sup>+</sup> T Cell Responses in the Etiologic Pathway to Endemic Burkitt Lymphoma
par: Catherine S. Forconi, et autres
Publié: (2021)

CD8+ T Lymphocytes Immune Depletion and LAG-3 Overexpression in Hodgkin Lymphoma Tumor Microenvironment Exposed to Anti-PD-1 Immunotherapy
par: Jean-Marie Michot, et autres
Publié: (2021)

KIFC1 Is Associated with Basal Type, Cisplatin Resistance, PD-L1 Expression and Poor Prognosis in Bladder Cancer
par: Yohei Sekino, et autres
Publié: (2021)

PD-L1 Inhibitors: Different Classes, Activities, and Mechanisms of Action
par: Ewa Surmiak, et autres
Publié: (2021)

Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach
par: Grimaud F, et autres
Publié: (2021)

Improved resection and prolonged overall survival with PD-1-IRDye800CW fluorescence probe-guided surgery and PD-1 adjuvant immunotherapy in 4T1 mouse model
par: Du Y, et autres
Publié: (2017)

High Inflammatory Tendency Induced by Malignant Stimulation Through Imbalance of CD28 and CTLA-4/PD-1 Contributes to Dopamine Neuron Injury
par: Dong L, et autres
Publié: (2021)

The effect of hypoxia on PD-L1 expression in bladder cancer
par: Vicky Smith, et autres
Publié: (2021)

Programmed death‐ligand 1 expression in swine chronic infections and enhancement of interleukin‐2 production via programmed death‐1/programmed death‐ligand 1 blockade
par: Otgontuya Ganbaatar, et autres
Publié: (2021)